olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.
Company profile
Ticker
OLMA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Olema Oncology Australia PTY LTD ...
IRS number
300409740
OLMA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
424B3
Prospectus supplement
12 Feb 24
EFFECT
Notice of effectiveness
12 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
7 Feb 24
S-3
Shelf registration
31 Jan 24
8-K
Olema Oncology JP Morgan Conference January 2024
8 Jan 24
8-K
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8 Jan 24
Latest ownership filings
4
Cyrus Harmon
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
4
Naseem Zojwalla
20 Mar 24
4
ANDREW RAPPAPORT
6 Mar 24
4
Cyrus Harmon
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Kynam Capital Management, LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 117.41 mm | 117.41 mm | 117.41 mm | 117.41 mm | 117.41 mm | 117.41 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.78 mm | 8.48 mm | 7.58 mm | 7.08 mm |
Cash used (since last report) | n/a | n/a | 51.46 mm | 56.09 mm | 50.15 mm | 46.83 mm |
Cash remaining | n/a | n/a | 65.94 mm | 61.31 mm | 67.26 mm | 70.58 mm |
Runway (months of cash) | n/a | n/a | 8.5 | 7.2 | 8.9 | 10.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 97 |
Opened positions | 18 |
Closed positions | 8 |
Increased positions | 36 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 576.41 bn |
Total shares | 56.43 mm |
Total puts | 36.20 k |
Total calls | 224.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 9.14 mm | $109.36 mm |
BVF | 9.14 mm | $112.83 bn |
Paradigm Biocapital Advisors | 7.80 mm | $96.37 bn |
Cormorant Asset Management | 4.50 mm | $55.63 bn |
Logos Global Management | 3.74 mm | $46.24 bn |
BLK Blackrock | 2.24 mm | $27.70 bn |
Deep Track Capital | 1.93 mm | $23.85 bn |
Vivo Capital | 1.87 mm | $23.14 bn |
MPM Oncology Impact Management | 1.86 mm | $22.94 bn |
Vanguard | 1.71 mm | $21.12 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Cyrus Harmon | Common Stock | Sell | Dispose S | No | Yes | 10.97 | 20,000 | 219.40 k | 826,283 |
18 Mar 24 | Naseem Zojwalla | Common Stock | Option exercise | Acquire M | No | No | 4.87 | 13,700 | 66.72 k | 80,364 |
18 Mar 24 | Naseem Zojwalla | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.87 | 13,700 | 66.72 k | 136,300 |
5 Mar 24 | Andrew Rappaport | Common Stock | Other | Acquire J | Yes | No | 0 | 385,965 | 0.00 | 385,965 |
5 Mar 24 | Andrew Rappaport | Common Stock | Other | Dispose J | Yes | No | 0 | 481,014 | 0.00 | 0 |
29 Feb 24 | Cyrus Harmon | Common Stock | Sell | Dispose S | No | Yes | 13 | 100 | 1.30 k | 846,283 |
29 Feb 24 | Cyrus Harmon | Common Stock | Sell | Dispose S | No | Yes | 12.41 | 24,900 | 309.01 k | 846,383 |
1 Feb 24 | Shane William Charles Kovacs | Stock Option Common Stock | Grant | Acquire A | No | No | 15.25 | 304,500 | 4.64 mm | 304,500 |
News
Goldman Sachs Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $24
2 Apr 24
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target
12 Mar 24
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25
12 Mar 24
Citigroup Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $20
30 Jan 24
Press releases
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
8 Apr 24
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
6 Mar 24
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Mar 24